After Pfizer, Serum Institute Seeks Approval For Emergency Nod Use Of Covishield


Pfizer seat emergency use authorization from DCGI, Drug Controller General of India, and the next day Serum Institute of India, SII, has applied for Covishield, covid-19 vaccine, Emergency Use Authorisation, EUA, in India.

The application has been submitted by SII and will be reviewed by the experts before they approve the vaccination by Covishield.

The vaccine produced by SII, in collaboration with the University of Oxford and AstraZeneca, is an active vaccine that triggered immunity response at a higher level in healthy adults between the ages 56 to 69 as well as people above 70 years.


Last month Prime Minister Mr. Narendra Modi also visited the SII facility to observe the research and experiments with a closer look.

Adar Poonawalla, Chief Executive Officer of SII, said, during a conference, that according to indications by the Prime Minister, it may be possible that the central government is in favor of buying 300 to 400 million doses by July 2021.

The company has currently produced 40 to 50 million doses and is looking forward to stretching their dozes to 100 million by February 2021.

The positive aspect of the Oxford Covid vaccine is that it could be stored at 8 degrees Celsius instead of the Pfizer vaccine which could have been stored at -70 degrees Celsius i.e. low temperatures only.

The result of the clinical trials on local Indians will be announced by December as soon as a UK authority’s will approve of it.

Currently, the use of the vaccine will be within a limited use but stockpiling of millions of doses will give the company a head start.

Within 3 to 4 months the vaccines will be made available to the general public.

See Also: Pfizer Requests For Emergency Use Authorization In India After Getting Approval From UK And Bahrain

Student with ambitions, writer with ideas.